SCHEMBL6073587

SCHEMBL6073587

Cc1cc(NC(=O)N(S)C2CCCCC2)nc2nc(Nc3ccc(N4CCNCC4)cc3)ncc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 20/20 0.55
CCND1 P24385 18/20 0.55
CCND3 P30281 15/20 0.55
CCND2 P30279 13/20 0.55
FGFR1 P11362 5/20 0.55
FGFR2 P21802 5/20 0.55
FGFR4 P22455 5/20 0.55
FGFR3 P22607 5/20 0.55
NUAK1 O60285 2/20 0.55
CCNA2 P20248 7/20 0.49
CDK2 P24941 7/20 0.49
CCNA1 P78396 5/20 0.49
PDGFRB P09619 1/20 0.49
PDGFRA P16234 1/20 0.49
CCNB2 O95067 3/20 0.48
CCNE2 O96020 3/20 0.48
CDK1 P06493 3/20 0.48
CCNB1 P14635 3/20 0.48
CCNE1 P24864 3/20 0.48
CCNB3 Q8WWL7 3/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6073534 0.86 CDK4 (0.56) CDK4CCND1CCND3CCND2FGFR1
SCHEMBL6073954 0.85 CDK4 (0.57) CDK4CCND1CCND3CCND2FGFR1
SCHEMBL6074744 0.83 CDK4 (0.56) CDK4CCND1CCND3CCND2FGFR1
SCHEMBL6073477 0.83 CDK4 (0.55) CDK4CCND1CCND3CCND2FGFR1
SCHEMBL6073583 0.83 CDK4 (0.56) CDK4CCND1CCND3CCND2FGFR1
SCHEMBL6073590 0.82 CDK4 (0.57) CDK4CCND1CCND3CCND2FGFR1
SCHEMBL6073860 0.80 CDK4 (0.53) CDK4CCND1CCND3CCND2FGFR1
SCHEMBL6073802 0.80 CDK4 (0.53) CDK4CCND1CCND3CCND2FGFR1
SCHEMBL6073673 0.79 CDK4 (0.51) CDK4CCND1CCND3CCND2FGFR1
SCHEMBL6073410 0.79 CDK4 (0.53) CDK4CCND1CCND3CCND2FGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7053070-B2 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors WARNER-LAMBERT COMPANY (US) 2006-05-30 US claimed
US-20030073668-A1 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors BOOTH RICHARD JOHN (US) 2003-04-17 US claimed
EP-1254137-A1 PYRIDO 2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2002-11-06 EP claimed
WO-2001055147-A1 PYRIDO[2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-08-02 WO claimed
US-7053070-B2 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors WARNER-LAMBERT COMPANY (US) 2006-05-30 US disclosed
US-20030073668-A1 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors BOOTH RICHARD JOHN (US) 2003-04-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073668-A1 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors CDK9, CDK19, CDK3 CDK4 19/4885CCND1 79/4885CCND3 98/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.